Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis

Janus kinase (JAK) inhibitors, a novel class of targeted synthetic disease-modifying antirheumatic drugs (DMARDs), have shown their safety and efficacy in rheumatoid arthritis (RA) and are being intensively tested in other autoimmune and inflammatory disorders. Targeting several cytokines with a sin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Przemysław J. Kotyla, Md Asiful Islam, Małgorzata Engelmann
Formato: Artigo
Lenguaje:Inglês
Publicado: MDPI AG 2020-10-01
Colección:International Journal of Molecular Sciences
Materias:
rheumatoid arthritis
JAK/STAT
Janus kinase inhibitors
cardiovascular system
heart failure
thromboembolic
Acceso en línea:https://www.mdpi.com/1422-0067/21/19/7390
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares